TobaccoReporter logo

Tag: Zyn

  • CAPHRA Says FDA’s Pouch Pivot Should Trigger Policy Rethink 

    CAPHRA Says FDA’s Pouch Pivot Should Trigger Policy Rethink 

    The Coalition of Asia Pacific Tobacco Harm Reduction Advocates is urging governments across the Asia-Pacific region to review the U.S. Food and Drug Administration’s recent authorization allowing 20 Zyn nicotine pouch products to carry reduced-risk claims for adult smokers. CAPHRA said the FDA’s decision recognizes the principle of relative risk following scientific review and should encourage regulators to distinguish between combustible cigarettes, high-risk smokeless tobacco products, and lower-risk smoke-free nicotine alternatives.

    The group called on policymakers to adopt evidence-based, risk-proportionate regulation, strengthen youth access restrictions and product standards, and ensure adult consumers receive accurate information about the comparative risks of nicotine products, arguing that treating all nicotine products as equally harmful undermines public health objectives.

  • FDA Issues MRTP Orders for 20 Zyn Products

    FDA Issues MRTP Orders for 20 Zyn Products

    The U.S. Food and Drug Administration issued Modified Risk Tobacco Product orders for 20 Zyn nicotine pouch products manufactured by Swedish Match USA, making Zyn the first nicotine pouch brand authorized to market reduced-risk claims compared with cigarettes. The FDA-authorized claim states that using Zyn instead of cigarettes lowers the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis. The authorization applies to 10 Zyn flavors in both 3 mg and 6 mg nicotine strengths and builds on the products’ January 2025 authorization for sale through the FDA’s premarket tobacco product application pathway.

    The FDA said its decision followed an extensive scientific review of the products’ relative health risks, consumer understanding of the claim, youth use data, and overall population health impact. The agency concluded that the modified-risk claim is scientifically supported, that consumers understand its meaning, and that allowing the claim is expected to benefit public health. The authorization requires Swedish Match USA to conduct post-market surveillance and behavioral studies, and the orders will expire after five years unless renewed. The FDA also noted it retains the authority to withdraw the orders if continued marketing no longer benefits public health, including if youth uptake increases.

    Separately, Philip Morris International said the decision expands its portfolio of FDA-authorized modified-risk products, which also includes IQOS heated tobacco products and General snus. PMI U.S. CEO Stacey Kennedy said the authorization provides adult nicotine consumers with FDA-reviewed, science-based information about the health benefits of switching completely from cigarettes to Zyn.

  • Haypp Announces Zyn Ultra Launch Across U.S.  

    Haypp Announces Zyn Ultra Launch Across U.S.  

    Haypp Group announced that Zyn Ultra nicotine pouches are available through its U.S. online retailers, Nicokick.com and Northerner.com, as of June 15. The new Zyn format contains 20 pouches per can, compared with 15 in the flagship lineup, and will initially launch in 9 mg strength across eight flavors, with an 11 mg range scheduled to follow later in June. Haypp said the rollout expands its portfolio of more than 300 nicotine pouch products and follows the resumption of direct-supplied Zyn sales in the U.S. in September 2025.

  • Health Canada Issues Recall for Zyn, Siberia Pouches

    Health Canada Issues Recall for Zyn, Siberia Pouches

    Health Canada issued a nationwide recall for Siberia and ZYN nicotine pouches last week, saying the products are being sold without market authorization. The recall covers Siberia 35 mg pouches and Zyn 6 mg varieties across multiple flavors and all lots, with officials classifying it as a Type II risk, meaning potential temporary health effects but low likelihood of serious harm.

    Consumers are advised to check whether their products are affected, contact their healthcare provider before stopping use, and report any adverse effects or safety concerns to Health Canada, which is also directing users to the recalling firm for further information.

  • Zyn Expanding Flavors in the Philippines

    Zyn Expanding Flavors in the Philippines

    Philip Morris International expanded its Zyn nicotine pouch portfolio in the Philippines with the introduction of new variants, including Cool Breeze in a 1.5mg strength and the Tropical flavor in 3mg and 6mg strengths. The update broadens the brand’s existing strength architecture in the market, which now spans 1.5mg, 3mg and 6mg across multiple flavors listed on its official Philippines website.

    According to the company, the 1.5mg Cool Breeze variant is positioned as a lower-strength option aimed at adult nicotine consumers who are new to nicotine pouches, while higher strengths will continue to serve existing users. The Tropical flavor is currently available in 3mg and 6mg formats, further expanding ZYN’s flavor range in the Philippines.

    The Philippine portfolio also includes several flavors such as Fresh Breeze, Dark Purple, and Espressino across different nicotine strengths.

  • PMI to Present at the dbAccess Global Consumer Conference

    PMI to Present at the dbAccess Global Consumer Conference

    Philip Morris International Inc. said it will host a live webcast of remarks and a Q&A session with CEO Jacek Olczak at the 2026 dbAccess Global Consumer Conference on June 2, at 11:15 a.m. CET. The session will be streamed live and made available for replay for one year via the company’s investor relations channels, including its mobile app and website.

    The event will provide an update on PMI’s strategy as it continues to position itself as a “smoke-free” consumer goods company, with a portfolio spanning cigarettes and reduced-risk products such as heat-not-burn devices, nicotine pouches, and e-vapor products. The company also highlighted ongoing regulatory milestones, including U.S. FDA authorizations for products such as Zyn nicotine pouches and IQOS devices, as it continues to expand its investor communications around its long-term transition strategy.

  • Tobacco-Free Kids Launches Campaign to End F1’s Tobacco Ties

    Tobacco-Free Kids Launches Campaign to End F1’s Tobacco Ties

    Today (March 28), the Campaign for Tobacco-Free Kids launched a new advertising initiative, “End the Formula,” ahead of the May 3 Miami Grand Prix, calling on Formula 1 to eliminate all tobacco-related sponsorships. The campaign targets partnerships between major F1 teams and companies, including Philip Morris International and British American Tobacco, which promote nicotine pouch and e-cigarette brands such as Zyn, Velo, and Vuse through branding on cars, driver apparel, and digital media. The campaign ties into similar efforts that began in March, which included ads, coordinated outreach with 162 organizations across 57 countries, and more than 25,000 petition messages urging F1 and affiliated partners to end these sponsorship arrangements.

  • Philippines Advocates Alleging Violations from Zyn, IQOS

    Philippines Advocates Alleging Violations from Zyn, IQOS

    Anti-smoking groups in the Philippines are calling on the Department of Trade and Industry (DTI) to act on complaints alleging violations of the Vape Regulation Act of 2022 by brands including Zyn and IQOS, according to the Sun Star. Advocacy organizations claim the products were promoted at public events such as the Sinulog Festival and through collaborations with artists, which they say are prohibited under the law that bans sponsorships and celebrity endorsements tied to nicotine products.

    Additional concerns were raised over product compliance, with some groups alleging that Zyn nicotine pouches are being sold without proper registration. The DTI, which has jurisdiction over vape-related regulation, is being urged to investigate and enforce existing rules, as advocates warn that continued non-compliance could increase youth exposure and undermine public health protections.

  • PM Plans Zyn Expansion in Tokyo

    PM Plans Zyn Expansion in Tokyo

    Philip Morris Japan announced it plans to expand sales of its oral nicotine pouch product “Zyn by IQOS” in Tokyo, with a broader rollout beginning May 11 across IQOS stores and convenience retailers. The product will be offered in Cool Mint, Spear Mint, Apple Mint, and Peach flavors, each with “low” and “medium” strength options. The company said the expansion reflects growing demand for discreet, smoke-free alternatives that can be used in a wider range of settings.

  • PMI Reduces Zyn Production in Owensboro

    PMI Reduces Zyn Production in Owensboro

    Philip Morris International announced it will scale back production at its Swedish Match facility in Owensboro, Kentucky, shifting part of its Zyn nicotine pouch operations from a 24/7 schedule to a 24/5 schedule beginning in early July, according to The Owensboro Times. The adjustment primarily affects the Zyn Flagship department, which will return to a five-day, three-shift model under the terms of the existing collective bargaining agreement.

    The company said the move reflects changing market conditions, with production currently exceeding demand following a period of rapid growth and capacity expansion. PMI invested more than $230 million into the Owensboro site in 2024, increasing output and adding approximately 450 jobs to support strong demand for Zyn products.

    PMI emphasized that the change is a production realignment rather than a reduction in long-term commitment to the facility, noting that other operations, including Zyn Ultra production and maintenance, will remain on a 24/7 schedule. The company said it will work with union leadership on staffing adjustments and indicated the schedule could return to continuous operations if demand increases.